EarningsQ2 2026 Earnings Report
DE:2K3 Q2 2026 EPS Results
Actual EPS-€0.08
Consensus EPS-€0.13
Beat/MissBeat by +€0.05
One Year Ago EPS-€0.12
DE:2K3 Q2 2026 Revenue Results
Actual Revenue€49.99M
Expected Revenue€49.39M
Beat/MissBeat by +€596.19K
YoY Revenue Growth+15.18%
Earnings Announcement Details
QuarterQ2 2026
Date08/03/2026
TimeAfter Close
Conference CallMonday, August 3, 2026
DE:2K3 Upcoming Earnings
SI-Bone's next earnings date is estimated for November 9, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:2K3 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong top-line growth, expanding physician adoption, robust gross margins, and meaningful improvement in adjusted EBITDA and cash balances. Management filed a 510(k) for a third breakthrough device, expects phased commercial launch in Q4, and benefited from favorable reimbursement actions (new DRGs and proposed SI joint increases). At the same time, the company remains modestly unprofitable on a GAAP basis, is investing in capacity and R&D which will cause near-term variability in cash flow and depreciation, and is taking a conservative view on near-term guidance due to seasonality and timing of catalysts. Overall, positives (growth, margin strength, reimbursement tailwinds, product pipeline and liquidity) outweigh near-term execution and timing risks.Company Guidance
Revenue Growth - Worldwide and U.S.
Worldwide revenue of $56.0M, up 15.2% year-over-year; U.S. revenue of $53.2M, up 14.7% year-over-year.
Strong Procedure and Physician Expansion
U.S. procedure volume up ~15% year-over-year and sequential U.S. procedure volume up ~9%; 1,715 unique physicians performed at least one procedure in Q2, a ~19% increase versus prior year.
International Momentum
International revenue grew 25.9% to $2.8M, driven by demand for TORQ and TNT and plans to expand product introductions and geographies.
Gross Profit and Margin Strength
Gross profit increased 14.8% to $44.5M and gross margin remained strong at 79.5%, supported by stable ASPs, product cost optimization, and improved surgical capacity utilization.
Improved Profitability and Adjusted EBITDA
Adjusted EBITDA improved 178% to $2.8M (adjusted EBITDA margin ~5.1%); trailing 12-month adjusted EBITDA quadrupled to $12.8M versus prior year period; net loss narrowed to $4.1M ($0.09 per diluted share) from $6.2M ($0.14).
Solid Liquidity and Positive Operating Cash Flow
Cash and equivalents of $145.9M (increase of ~$1.3M sequentially) and multiple recent quarters of positive operating cash flow, providing capacity to fund development programs.
Commercial Scalability and Territory Productivity
93 quota-carrying territory managers with trailing 12-month revenue per territory of ~$2.2M; company expects to approach ~100 territories by year-end to support upcoming launches.
Regulatory & Reimbursement Catalysts
510(k) filed in June for a third breakthrough device (targeted phased commercial launch as early as October); CMS proposed higher outpatient/ASC/OBL reimbursement for SI joint fusion and finalized new DRGs that could increase hospital payments for complex spinal fusion (including Granite) by up to ~$50k per procedure.
DE:2K3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed